TABLE 3

Medications used for treatment of granulomatous lymphocytic interstitial lung disease and lung function results before and after treatment

GroupTime monthsPFTBefore treatmentAfter treatmentp-value
Acute corticosteroid 0.5–1 mg·kg−1 daily3.8FVC%77 (50–95)74 (54–110)0.09
FEV1%77 (42–96)73 (48–96)0.92
DLCO%59 (43–69)66 (57–86)0.04
Mycophenolate mofetil 500–1000 mg twice a day46FVC%79 (71–102)89 (72–102)0.35
FEV1%74 (66–100)81 (73–102)0.08
DLCO%63 (55–75)72 (67–79)0.04
Immunoglobulin replacement only
400–800 mg·kg−1 3-weekly
94FVC%92 (80–95)72 (65–89)#
FEV1%82 (53–85)57 (46–83)#
DLCO%77 (69–90)64 (54–68)#

Data are presented as median (interquartile range), unless otherwise stated. PFT: pulmonary function test; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide. #: no significant difference compared with pre-treatment period due to small group numbers.